Значение фосфатбиндеров в лечении минеральных и костных нарушений при хронической болезни почек с учетом центральной роли нарушения гомеостаза фосфора в их формировании (обзор литературы)


Н.А. Михайлова

Кафедра нефрологии и гемодиализа ГБОУ ДПО РМАПО МЗ РФ, Москва
В статье обсуждается нарушение обмена фосфатов и его последствия у больных с хронической болезнью почек. Приведен весь спектр существующих фосфатбиндеров, их сравнительные характеристики и опыт применения в клинической практике.

Литература


1. Schiavi S.C., Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int, 2004, 65:1–14.
2. Dusso A.S., Brown A.I., Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289: F8–28.
3. Berndt T, Kumar R. Phosphatonins and the regulationof phosphate homeostasis. Ann Rev Physiol. 2007; 69:341–359.
4. Goetz R., Beenken A., Ibrahimi O.A. et al. Molecular insightsinto the Klothodependent, endocrine modeof action of FGF19 subfamily members. Mol Cell Biol. 2007;27:3417–3428.
5. Kuro-o M., Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab. 2008; 19:239–245.
6. Kuro-o M., Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens. 2006; 15:437–441.
7. Shimada T., Kakitani M., Yamazaki I. et al. Targeted ablationof Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561–568.
8. Kurosu H., Ogawa Y., Miyoshi M. et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006, 281:6120–6123.
9. Urakawa I., Yamazaki Y., Shimada T. et al. Klotho converts canonical FGF receptor into a speciphic receptorfor FGF23. Nature. 2006, 444:770–774.
10. Kuro-o M. Klotho and ageing. Biochim Biophys Acta, 2009, 1790:1049– 1058.
11. Ketteler M., Schlieper G., Floege J. Calcification and cardiovascular health: new insight into an old phenomenon. Hypertension. 2006;47:1027–1034.
12. Giachelli C.M. Vascular calcification mechanisms. J Am Soc Nephrol. 2004;15:2959–2964.
13. Block G.A., Hulbert-Shearon T.E., Levin N.W. et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4): 607–617.
14. Block G.A., Klassen P.S., Lazarus J.M. et al. Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8): 2208–2218.
15. Young E.W., Albert J.M., Satayathum S. et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179–1187.
16. Covic A., Kothawala P., Bernal M. et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. NDT 2009;24:1506–1523.
17. Foley R.N., Collins A.J., Herzog C.A. et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009;20(2): 397–404.
18. Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520–528.
19. Tonell M., Sacks F., Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627–2633.
20. Sigrist M.K., Taal M.W., Bungay P., McIntyre C.W. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(6):1241–1248.
21. Dhingra R., Sullivan L.M., Fox C.S. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879–885.
22. Foley R.N., Collins A.J., Ishani A. et al. Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:556–563.
23. Foley R.N. Phosphate levels and cardiovascular disease in the general population. Clin J Am Soc Nephrol. 2009;4(6):1136–1139.
24. Foley R.N, Collins A.J., Herzog C.A. et al. Serum phosphate and left ventricular hypertrophy in young adults: the coronary artery risk development in young adult study. Kidney Blood Press Res. 2009;32:37–44.
25. Tentory F, Blayney MJ, Albert JM. et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52:519–530.
26. Wills MR, Savory J. Aluminium poisoning: dialysis encephalopathy, osteomalacia and anemia. Lancet. 1983;2:29–34.
27. Altmann P. Aluminium toxicity in dialysis patients: no evidence for a threshold serum aluminium concentration. NDT. 1993;8(Suppl. 1):525–534.
28. Siem X. Uber die Wirkung des Aluminiums, unter besonderer Berucksichtigung der durch das Aluminium verursachten Lasionen in Zentralhervensistem. Naunyn Schmiedebergs Arch Pharmacol. 1897;40:58–120.
29. Spaffarth J. Case of aluminium poisoning. Lancet. 1921:i:1301.
30. Alfrey A.C., LeGendre G.R., Kaehny W.D. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N Engl J Med. 1976;294:184–88.
31. Altmann P., Dhanesha U., Hamon C. et al. Disturbance of cerebral function by aluminium in hemodialysis patients without overt aluminium toxicity. Lancet. 1989;2:7–12.
32. Damment S., Autissier V., Henderson R. Influence of Bile Acids on the Phosphate-Binding Efficacy of Lanthanum Carbonate and Sevelamer Hydrochloride. ASN Renal week 2007 abstracts SA-PO866.
33. Zhang Q., Li M., Lu Y. et al. Meta-analysis comparing sevelamer and calciumbased phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract. 2010;115(4):259–267.
34. Chertow G.M., Burke S.K., Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252.
35. Block G.A., Spiegel D.M., Ehrlich J. et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824.
36. Qunibi W., Moustafa M., Muenz L.R. et al. CARE-2 Investigators. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis.
2008;51:952–965.
37. Barreto D.V., Barreto F. de C., de Carvalho A.B. et al. Phosphate binder impact on bone remodeling and coronary calcification – results of the BRiC study. Nephron Clin Pract. 2008;110:273–283. 38. Lin H.-H., Huang C.-C. Comparison of 48-week treatment of sevelamer and calcium carbonate on serum fibroblast growth factor 23, klotho and fetuin-A in chronic hemodialysis patients: A randomized, open-label, parallel-group study. ISN Nexus Symposium Bone and the Kidney, Sept. 20-23, 2012, Copenhagen,
Denmark, Abstract 100.
39. Pennick M., Dennis K., Damment S.J.P. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J Clin Pharm. 2006, 46:738–746.
40. Evans C.H. The occurrence and metabolism of lanthanides. In: Biochemistry of the Lanthanides. Plenum Press: New York, 1990, 285–337.
41. Damment S.J.P, Greaves P., Downes N. The Toxicology of Lanthanum Carbonate (Fosrenol®), a New Non-Aluminum, Non-Calcium Phosphate Binder. ASN Renal week 2003 abstracts F-PO651.
42. Hutchison A., Maes B., Vanwalleghem J. et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphataemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:8–19.
43. Behets G.J., Dams G., Damment S.J.P. et al. Differencesin gastrointestinal calcium absorbtionafter ingestion of non calcium-containing phosphate binders. ISN Nexus Symposium Bone and the Kidney, Sept. 20–23, 2012, Copenhagen, Denmark, Abstract 98.
44. Caravaca F.,• Santos I.,• Cubero J.J. et al. Calcium Acetate versus Calcium Carbonate as Phosphate Binders in Hemodialysis Patients. Nephron. 1992, 60:423–427.
45. Emmett M. A comparison of calcium-based phosphorus binders for patients with chronic kidney disease. D&T. 2006;35:284–293.
46. Whang R., Ryder K.W. Frequency of Hypomagnesemia and Hypermagnesemia Requested vs Routine. JAMA. 1990;263(22):3063–3064.
47. Kikuchi K., Tanaka H., Gima M. et al Abnormalities of Magnesium (Mg) Metabolism and Therapeutic Significance of Mg Administration in Patients with Metabolic Syndrome, Type 2 Diabetes, Heart Failure and Chronic Hemodialysis. Clin Calcium. 2012;22(8):1217–1226.
48. He K., Liu K., Daviglus M.L. et al. Magnesium intake and incidence of metabolic syndrome among young adults. Circulation. 2006;113:1675–1682.
49. Touyz RM. Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. Am J Physiol Heart Circ Physiol. 2008;294:H1103–H1118.
50. Ishimura E.I., Okuno S., Yamakawa T. et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnesium Research. 2007;20(4):237–244.
51. Ishimura E., Okuno S., Kitatani K. et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol 2007;68:222–227.
52. Salem S., Bruck H., Bahlmann F.H. et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol. 2012;35(1):31–39.
53. Kircelli F., Peter M.E., Ok E.S. et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant. 2012;27:514–521.
54. Peters F., Epple M. Simulating arterial wall calcification in vitro: biomimetic crystallization of calcium phosphates under controlled conditions. Z Kardiol 2001;90(Suppl. 3):81–85.
55. De Francisco A.L.M., Leidig M., Covic A.C. et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) accessing efficacy and tolerability. NDT. 2010;25:3707– 3717.
56. Shobeiri N, Cruanes J, Curtis M. et al. Magnesium status is an underrecognized an potentially modifiable risk factor in CKD. ISN Nexus Symposium Bone and the Kidney, Sept. 20–23, 2012, Copenhagen, Denmark, Abstract 153.
57. De Schutter T.M., Neven E., Behets G.J. et al. Effect of a magnesium-based phosphate binder on the development of media calcifications in a rat model of adenine-induced uremia. A comparative multiple dose study. ISN Nexus Symposium Bone and the Kidney, Sept. 20–23, 2012, Copenhagen, Denmark, Abstract 85.
58. Russo D, Miranda I, Ruocco C. et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–1261.
59. Block G.A., Wheeler D.C., Persky M.S. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23:1407–1415.
60. Drüeke T.B., Massy Z.A. Phosphate binders in CKD: bad news or good news? J Am Soc Nephrol. 2012;23:1277–1280.


Об авторах / Для корреспонденции


Михайлова Н.А. – доцент кафедры нефрологии и гемодиализа ГБОУ ДПО РМАПО Минздрава России, к.м.н.
Тел. 8 (499) 252-52-88


Похожие статьи


Бионика Медиа